Showing results (81-90 of 105) with videos related to
Sort By:
Pageof 11
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 1, 2020
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitisFabio Salvatore Macaluso, Marco Ventimiglia, Walter Fries, et al.Gut|January 29, 2011
H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapyJean-François Rahier, Pavol Papay, Julia Salleron, et al.Journal of Crohn'S & Colitis|March 18, 2014
Early post-operative endoscopic recurrence in Crohn's disease patients: data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohortAmbrogio Orlando, Filippo Mocciaro, Sara Renna, et al.Drugs & Aging|February 5, 2020
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)Serena Porcari, Anna Viola, Ambrogio Orlando, et al.Journal of Gastroenterology and Hepatology|May 6, 2023
Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's diseaseFabio Salvatore Macaluso, Mauro Grova, Filippo Mocciaro, et al.Inflammatory Bowel Diseases|April 6, 2022
Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19Fabio Salvatore Macaluso, Alessandra Giuliano, Walter Fries, et al.Journal of Gastroenterology and Hepatology|June 21, 2021
SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501Fabio Salvatore Macaluso, Maria Cappello, Anita Busacca, et al.United European Gastroenterology Journal|June 20, 2026
Induction and Prolonged Induction With Mirikizumab in Ulcerative Colitis-A Prospective, Real-World Study From the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)Giuseppe Costantino, Anna Viola, Andrea Iuculano, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 6, 2017
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)Livia Biancone, Vito Annese, Sandro Ardizzone, et al.Journal of Crohn'S & Colitis|October 9, 2018
A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel DiseaseFabio Salvatore Macaluso, Walter Fries, Antonio Carlo Privitera, et al.Pageof 11